Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

09-482 Anti-PI3 Kinase Antibody, p110β

09-482
100 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, Mk, Ca, M, RWB, IP, ICC, IHC, ELISARbAffinity PurifiedPolyclonal Antibody
Description
Catalogue Number09-482
Replaces04-399
DescriptionAnti-PI3 Kinase Antibody, p110β
Alternate Names
  • PI3-kinase p110 subunit alpha
  • phosphatidylinositol 3-kinase, catalytic, 110-KD
  • alpha
  • PtdIns-3-kinase p110
  • phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
  • phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform
  • phosphoinositide-3-kinase, catalytic, alpha polypeptide
Background InformationPI3 Kinase (Phosphatidylinositol 3-Kinase) is responsible for phosphorylation of the 3 position of the inositol ring of PI(4,5)P2, to generate PI(3,4,5)P3, a potent second messenger required for survival, signaling, and insulin action. PI3 Kinase is a heterodimeric complex composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. Tyrosine phosphorylation of growth factor receptors creates docking sites for binding of p85 (through its SH2 domains) on the receptors; p85 brings with it p110, which is then proximal to its phospho-lipid substrate on the membrane. PI3 Kinase is also activated by Ras, and by the β:γ subunits of heterotrimeric G-proteins. PI3 Kinase is inhibitable by wortmannin, a useful tool for the study of the PI3 Kinase signaling pathway.
References
Product Information
FormatAffinity Purified
HS Code3002 15 90
Control
  • HEK-293 cell lysate.
PresentationAntigen affinity purified rabbit serum in 0.1M Tris-Glycine (pH7.4), 150mM NaCl, with 0.05% NaN3.
Quality LevelMQ100
Applications
ApplicationAnti-PI3 Kinase Antibody, p110β is an antibody against PI3 Kinase for use in WB, IP, IC, IH, ELISA.
Key Applications
  • Western Blotting
  • Immunoprecipitation
  • Immunocytochemistry
  • Immunohistochemistry
  • ELISA
Application NotesELISA:
This antibody was tested and determined to work for ELISA at 0.5 ng/well.
Biological Information
ImmunogenKLH-conjugated synthetic linear peptide corresponding to the internal domain of PI3 Kinase, p110β.
EpitopeInternal Domain
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityRecognizes the internal domain of PI3 Kinase, p110β.
Species Reactivity
  • Human
  • Monkey
  • Canine
  • Mouse
  • Rat
Species Reactivity NoteHuman. Expected to react with Monkey, Dog, Rat and Mouse based on immunogen sequence homology.
Antibody TypePolyclonal Antibody
Entrez Gene Number
Gene Symbol
  • EC 2.7.1.153
  • MGC142161
  • MGC142163
  • PI3K
  • p110-alpha
Purification MethodAffinity Purfied
UniProt Number
UniProt SummaryFUNCTION: Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.

CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.

SUBUNIT STRUCTURE: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3 By similarity.

INVOLVEMENT IN DISEASE: Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].

Defects in PIK3CA are associated with breast cancer [MIM:114480].

Defects in PIK3CA are associated with epithelial ovarian cancer (EOC) [MIM:604370].

Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. Ref.14

PI3KCA mutations affecting exons 9 and 20 display gender- and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles.

SEQUENCE SIMILARITIES: Belongs to the PI3/PI4-kinase family.

Contains 1 C2 domain.

Contains 1 PI3K/PI4K domain.

Molecular Weight110 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blot on HEK-293 cell lysate.
Western Blot Analysis: 0.05 - 0.1 μg/mL of this antibody detected endogenous PI3 Kinase, p110β in lysate from HEK-293 cells.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
09-482 04053252730627

Documentation

Anti-PI3 Kinase Antibody, p110β SDS

Title

Safety Data Sheet (SDS) 

Anti-PI3 Kinase Antibody, p110β Certificates of Analysis

TitleLot Number
Anti-PI3 Kinase, p110 - 2266487 2266487
Anti-PI3 Kinase, p110 - 2278492 2278492
Anti-PI3 Kinase, p110 - 2364189 2364189
Anti-PI3 Kinase, p110 - NG1607964 NG1607964
Anti-PI3 Kinase, p110 - NG1686570 NG1686570
Anti-PI3 Kinase, p110 - NG1740987 NG1740987
Anti-PI3 Kinase, p110 - NG1927068 NG1927068
Anti-PI3 Kinase, p110β - 2410228 2410228
Anti-PI3 Kinase, p110β - 2437357 2437357
Anti-PI3 Kinase, p110β - 3485497 3485497

References

Reference overviewPub Med ID
Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles.
Yi-Cheng Huang,Ting-Ju Liu
Acta biomaterialia  8  2012

Show Abstract
22200609 22200609